PL317197A1 - Compositions for and method of treating sclerosis multiplex - Google Patents

Compositions for and method of treating sclerosis multiplex

Info

Publication number
PL317197A1
PL317197A1 PL95317197A PL31719795A PL317197A1 PL 317197 A1 PL317197 A1 PL 317197A1 PL 95317197 A PL95317197 A PL 95317197A PL 31719795 A PL31719795 A PL 31719795A PL 317197 A1 PL317197 A1 PL 317197A1
Authority
PL
Poland
Prior art keywords
compositions
sclerosis multiplex
treating sclerosis
treating
multiplex
Prior art date
Application number
PL95317197A
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL317197A1 publication Critical patent/PL317197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL95317197A 1994-05-10 1995-05-04 Compositions for and method of treating sclerosis multiplex PL317197A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US32822494A 1994-10-25 1994-10-25

Publications (1)

Publication Number Publication Date
PL317197A1 true PL317197A1 (en) 1997-03-17

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95317197A PL317197A1 (en) 1994-05-10 1995-05-04 Compositions for and method of treating sclerosis multiplex

Country Status (11)

Country Link
EP (1) EP0758902A1 (en)
JP (1) JPH10500109A (en)
AU (1) AU2470595A (en)
CA (1) CA2189990A1 (en)
CZ (1) CZ329596A3 (en)
HU (1) HUT76099A (en)
IL (1) IL113661A0 (en)
PL (1) PL317197A1 (en)
SI (1) SI9520059A (en)
SK (1) SK145896A3 (en)
WO (1) WO1995030435A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77047A (en) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
CN102784385B (en) * 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 Peptide selection method
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CN1656222B (en) 2002-03-27 2011-11-30 艾格拉治疗公司 Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (en) 2008-04-08 2016-02-29 Tigo Gmbh Inhibitor of endogenous human interferon - gamma
BG1430U1 (en) * 2010-06-25 2011-04-29 Иван ИВАНОВ Pharmaceutical formulation
BG67190B1 (en) 2017-03-29 2020-11-16 Tigo Gmbh Anti-gama mutant protein against endogenous human gamma interferon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212358T1 (en) * 1992-04-09 2002-02-15 Autoimmune Inc SUPPRESSION OF T-CELL PROLIFERATION USING PEPTIDE FRAGMENTS OF BASIC PROTEIN FROM MYELIN
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Also Published As

Publication number Publication date
WO1995030435A2 (en) 1995-11-16
AU2470595A (en) 1995-11-29
CA2189990A1 (en) 1995-11-16
EP0758902A1 (en) 1997-02-26
CZ329596A3 (en) 1997-05-14
SK145896A3 (en) 1997-05-07
HUT76099A (en) 1997-06-30
JPH10500109A (en) 1998-01-06
WO1995030435A3 (en) 1995-12-07
SI9520059A (en) 1997-08-31
IL113661A0 (en) 1995-08-31
HU9603116D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
PL320487A1 (en) Haemorrhoidal compositions and method of applying them
PL324970A1 (en) Method of and composition for treating asthma
EP0771203A4 (en) Method of treating sweat-related conditions
US5683503B1 (en) Composition for and method of pumping concrete
PL333364A1 (en) Novel compounds and method of using them
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
EP0850042A4 (en) Composition and method for remineralization of teeth
AP9300598A0 (en) Compositions and method for waste treatment
PL327617A1 (en) Compositions for and methods of treating osseous insufficiency
EP0758242A4 (en) Composition and method for treatment of cmv infection
PL329893A1 (en) Method of and compositions for treating and preventing hyperuricaemia
GB9520615D0 (en) Method of preventing bone loss
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
EP0975654A4 (en) Composition and method for treatment of cmv infections
ZA931778B (en) Method and composition for the treatment of osteoporosis
PL321204A1 (en) Compositions for peroxiding creatine fibres and method of using such compositions
GB9517111D0 (en) Surface-coating composition and method of application
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
GB2296718B (en) Method for infrared-activated curing of polyorganosiloxane compositions
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
EP0692965A4 (en) Method and composition for treatment of osteoporosis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
AU7379296A (en) Method and composition for treatment of osteoporosis
GB9415902D0 (en) Method of treatment
PL306631A1 (en) Match-head composition and method of obtaining same